clinical trial · NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer RecurrentIpilimumabNivolumabNogapendekin alfa inbakicept
brief summary
This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.
started
Jul 31, 2026
primary completion
Jul 31, 2032
completion
Jul 31, 2032
last updated
Jul 2, 2026
official title
A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol